Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast (original) (raw)

• Acosta JC, Richard C, Delgado MD, Horita M, Rizzo MG, Fernadez-Luna JL et al. (2003). Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol Cancer Ther 2: 893–900.
  CAS PubMed Google Scholar
• Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B et al. (2001). p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 20: 3573–3579.
  Article CAS PubMed Google Scholar
• Cho Y, Gorina S, Jeffrey PD, Pavletich NP . (1994). Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346–355.
  Article CAS PubMed Google Scholar
• Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW et al. (2007). Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 28: 289–298.
  Article CAS PubMed Google Scholar
• Di Como CJ, Prives C . (1998). Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene 16: 2527–2539.
  Article CAS PubMed Google Scholar
• DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC et al. (2002). A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 1: 12–16.
  Article Google Scholar
• Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P et al. (1995). A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92: 3963–3967.
  Article CAS PubMed Google Scholar
• Flaman JM, Rober V, Lenglet S, Moreau V, Iggo R, Frebourg T . (1998). Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assay in yeast. Oncogene 16: 1369–1372.
  Article CAS PubMed Google Scholar
• Friedlander P, Haupt Y, Prives C, Oren M . (1996). A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 16: 4961–4971.
  Article CAS PubMed PubMed Central Google Scholar
• Gaitonde SV, Riley JR, Qiao D, Martinez JD . (2000). Conformational phenotype of p53 is linked to nuclear translocation. Oncogene 19: 4042–4049.
  Article CAS PubMed Google Scholar
• Gannon JV, Greaves R, Iggo R, Lane DP . (1990). Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 12: 1595–1602.
  Article Google Scholar
• Hansen S, Hupp TR, Lane DP . (1996). Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. J Biol Chem 271: 3917–3924.
  Article CAS PubMed Google Scholar
• Inga A, Storici F, Darden TA, Resnick MA . (2002). Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 22: 8612–8625.
  Article CAS PubMed PubMed Central Google Scholar
• Ishioka C, Frebourg T, Yan YX, Vidal M, Friend SH, Schmidt S et al. (1993). Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 5: 124–129.
  Article CAS PubMed Google Scholar
• Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T et al. (1997). Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog 19: 243–253.
  Article CAS PubMed Google Scholar
• Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R et al. (2003). Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100: 8424–8429.
  Article CAS PubMed Google Scholar
• Lane PD, Hupp TR . (2003). Drug discovery and p53. Drug Discov Today 8: 347–355.
  Article CAS PubMed Google Scholar
• Levine AJ, Hu W, Feng Z . (2006). The p53 pathway: what questions remain to be explored? Cell Death Differ 13: 1027–1036.
  Article CAS PubMed Google Scholar
• Ludwig RL, Bates S, Vousden KH . (1996). Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 16: 4952–4960.
  Article CAS PubMed PubMed Central Google Scholar
• Maurici D, Monti P, Campomenosi P, North S, Frebourg T, Fronza G et al. (2001). Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene 20: 3533–3540.
  Article CAS PubMed Google Scholar
• McLure KG, Lee PWK . (1999). P53 DNA binding can be modulated by factors that alter the conformational equilibrium. EMBO J 18: 763–770.
  Article CAS PubMed PubMed Central Google Scholar
• Milner J, Cook A, Sheldon H . (1987). A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40. Oncogene 1: 453–455.
  CAS PubMed Google Scholar
• Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P et al. (2005). Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 207: 251–259.
  Article CAS PubMed Google Scholar
• North S, El-Ghissassi F, Pluquet O, Vergaegh G, Hainaut P . (2000). The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 9: 1206–1214.
  Article Google Scholar
• North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P . (2002). Restoration of wild-type conformation and activity of temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol Carcinog 33: 181–188.
  Article CAS PubMed Google Scholar
• Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P . (2002). The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607–614.
  Article CAS PubMed Google Scholar
• Ory K, Legros Y, Auguin C, Soussi T . (1994). Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13: 3496–3504.
  Article CAS PubMed PubMed Central Google Scholar
• Pataer A, Fanale MA, Roth JA, Swisher SG, Hunt KK . (2006). Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53. Cancer Gene Ther 13: 806–814.
  Article CAS PubMed Google Scholar
• Pavlova S, Mayer J, Koukalova H, Smardova J . (2003). High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast. Int J Oncol 23: 121–131.
  CAS PubMed Google Scholar
• Petitjean A, Achatz MIW, Borresen-Dale AL, Hainaut P, Olivier M . (2007). TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26: 2157–2165.
  Article CAS PubMed Google Scholar
• Resnick MA, Inga A . (2003). Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 100: 9934–9939.
  Article CAS PubMed Google Scholar
• Scharer E, Iggo R . (1992). Mammalian p53 can function as a transcription factor in yeast. Nucl Acid Res 20: 1539–1545.
  Article CAS Google Scholar
• Selivanova G, Wiman KG . (2007). Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26: 2243–2254.
  Article CAS PubMed Google Scholar
• Shiraishi K, Kato S, Han SY, Lui W, Otsuka K, Sakayori M et al. (2004). Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 279: 348–355.
  Article CAS PubMed Google Scholar
• Smardova J, Ksicova K, Binkova H, Pavlova S, Rottenberg J, Koukalova H . (2004). Analysis of tumor suppressor p53 status in head and neck squamous cell carcinoma. Oncol Rep 11: 923–929.
  CAS PubMed Google Scholar
• Smardova J, Nemajerova A, Trbusek M, Vagunda V, Kovarik J . (2001). Rare somatic p53 mutation identified in breast cancer: a case report. Tumor Biol 22: 59–66.
  Article CAS Google Scholar
• Smardova J, Smarda J, Koptikova J . (2005). Functional analysis of p53 tumor suppressor in yeast. Differentiation 73: 261–277.
  Article CAS PubMed Google Scholar
• Stephen CW, Lane DP . (1992). Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol 22: 577–583.
  Article Google Scholar
• Xirodimas DP, Lane DP . (1999). Molecular evolution of the thermosensitive PAb1620 epitope of human p53 by DNA shuffling. J Biol Chem 274: 28042–28049.
  Article CAS PubMed Google Scholar
• Zhang W, Guo XY, Hu GY, Liu WB, Shay JW, Deisseroth AB . (1994). A temperature-sensitive mutant of human p53. EMBO J 13: 2535–2544.
  Article CAS PubMed PubMed Central Google Scholar